Bayer flags $750 million larger Roundup settlement invoice

© Reuters. FILE PHOTO: Historical facade of Bayer AG headquarters of German pharmaceutical and chemical maker in Leverkusen

FRANKFURT (Reuters) – Drugs and farming pesticides maker Bayer (DE:) said the costs of its settlement over claims its Roundup weedkiller causes cancer, initially put at $11 billion, would be $750 million higher.

Bayer struck an agreement in principle with U.S. plaintiff’s lawyers in June but a judge later took issue with a side arrangement on future cases that may yet be lodged, known as a class plan.

“Bayer took an additional provision in the third quarter to cover the increased cost of a revised class plan, as it is far enough along in the negotiations to know that the new plan will come in at approximately 2 billion U.S. dollars, an increase over the original cost of 1.25 billion U.S. dollars,” Bayer said in a statement on Monday.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Comments are closed.